• 대한바이러스학회지
• /
• 제30권1호
• /
• pp.11-18
• /
• 2000

Since $Hantavax^{TM}$, formalin inactivated Hantaan virus vaccine (10,240 ELISA units/ml), has been developed in 1990 to prevent against haemorrhagic fever with renal syndrome (HFRS) caused by Hantaan or Seoul virus, it has been commercially available in Korea. Twenty-one healthy people were booster shot once and twice after primary basic vaccination with $Hantavax^{TM}$. Seroconversion rates were measured by immunofluorescent antibody technique (IFAT), enzyme-linked immunosorbent assay (ELISA), high density composite particle agglutination (HDPA), and plaque reduction neutralization test (PRNT). Seroconversion rates of 21 vaccinees at one year after primary basic vaccination were 52.3%, 95.2%, 0.0%, 47.6%, and 28.6%, and 13 vaccinees at one month after 1st booster vaccination were 100%, 100%, 30.7%, 100% and 100% by IFAT, ELISA (IgG, IgM), HDPA and PRNT, respectively. Seroconversion rates declined slightly by twenty months, and they were 84.6%, 92.3%, 0.0%, 84.6% and 69.2% by IFAT, ELISA (IgG, IgM), HDPA and PRNT, respectively. Seroconversion rates of 9 vaccinees at three months after 2nd booster vaccination were 100%, 100%, 0.0%, 100%, and 88.9%, and 16 vaccinees at one year after the 2nd booster vaccination were 87.5%, 93.8%, 0.0%, 87.5% and 81.3% by IFAT, ELISA (IgG, IgM), HDPA and PRNT, respectively. Based on the above result $Hantavax^{TM}$ has proved a vigorous anamnestic response after the 1st and the 2nd booster vaccination and has persisted higher fluorescence, agglutination and neutralizing antibody titers in vaccinees.

• Journal of Preventive Medicine and Public Health
• /
• 제42권2호
• /
• pp.104-108
• /
• 2009

Objectives : To increase the booster vaccination rate, the Korean government legislated a measles vaccination for elementary school students in 2001, requiring parents to submit a certificate of vaccination upon the admission of the students to elementary school. The purpose of this study was to evaluate the validity of measles vaccination certificates which were issued to parents. Methods : Using questionnaire survey data of 890 general practitioners and 9,235 parents in 2005, we investigated the evidence for booster vaccination certificates of measles. Results : In the survey of general practitioners, 59.5% of the certificates depended on the medical records of clinic, 13.5% was immunization booklets, 23.7% was reimmunizations, 1.9% was confirmation of record of other clinics, and 1.4% was parents statements or requests without evidence. In the survey of parents, 36.2% of the certificates depended on the medical records of clinic, 43.4% was immunization booklets, 18.0% was reimmunizations, and 2.4% was parents statements or requests without evidence. Conclusions : Our findings show that a majority of the booster vaccination certificates of measles was issued on the basis of documented vaccinations and it means that the implementation of the law requiring the submission of elementary school students' vaccination certificates has been very successful in Korea.

• Clinical and Experimental Vaccine Research
• /
• 제12권1호
• /
• pp.60-69
• /
• 2023

Purpose: Although the fast development of safe and effective messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 has been a success, waning humoral immunity has led to the recommendation of booster immunization. However, knowledge of the humoral immune response to different booster strategies and the association with adverse reactions is limited. Materials and Methods: We investigated adverse reactions and anti-spike protein immunoglobulin G (IgG) concentrations among health care workers who received primary immunization with mRNA-1273 and booster immunization with mRNA-1273 or BNT162b2. Results: Adverse reactions were reported by 85.1% after the first dose, 94.7% after the second dose, 87.5% after a third dose of BNT162b2, and 86.0% after a third dose of mRNA-1273. They lasted for a median of 1.8, 2.0, 2.5, and 1.8 days, respectively; 6.4%, 43.6%, and 21.0% of the participants were unable to work after the first, second, and third vaccination, respectively, which should be considered when scheduling vaccinations among essential workers. Booster immunization induced a 13.75-fold (interquartile range, 9.30-24.47) increase of anti-spike protein IgG concentrations with significantly higher concentrations after homologous compared to heterologous vaccination. We found an association between fever, chills, and arthralgia after the second vaccination and anti-spike protein IgG concentrations indicating a linkage between adverse reactions, inflammation, and humoral immune response. Conclusion: Further investigations should focus on the possible advantages of homologous and heterologous booster vaccinations and their capability of stimulating memory B-cells. Additionally, understanding inflammatory processes induced by mRNA vaccines might help to improve reactogenicity while maintaining immunogenicity and efficacy.

• Asian-Australasian Journal of Animal Sciences
• /
• 제14권4호
• /
• pp.559-563
• /
• 2001

The effects of feeding a mannan oligosaccharide (Bio-Mos) from 0 to 3 g/kg diet and vaccination program on 1- to 35-day performance (growth and feed efficiency), metabolizable energy, nitrogen utilization and carcass composition of meat chickens were investigated. A general vaccination program was used against IB, IBD and ND with half of the birds per diet receiving a booster dose of IB and ND vaccines at 12 days of age. Dietary supplementation of Bio-Mos (BM) did not influence body weight gain, feed efficiency and nutrient utilization. The highest dietary BM (3 versus 1.5 or 0 g/kg) increased carcass abdominal fat and reduced the proportion of drumstick in the carcass of meat chickens. The booster dose reduced the performance of birds. It was concluded that the addition of BM to the diet of chickens did not significantly influence the performance and nutrient utilization of meat chickens.

• Clinical and Experimental Pediatrics
• /
• 제54권4호
• /
• pp.163-168
• /
• 2011

Purpose: The purpose of this study was to evaluate the immune response to serotype 19A in children aged 12-23 months after immunization of the 19F containing 7-valent pneumococcal conjugate vaccine (PCV7). Methods: Blood samples from a total of 45 subjects (age 12-23 months) were included in the study. Subjects were categorized according to immunization status into three groups as follows: 18 subjects with 3 primary doses and 1 booster dose of PCV7 (booster group), 21 subjects with 3 primary doses before 12 months of age (primary group), and 6 subjects with no vaccination history of PCV7 (control group). An ELISA and opsonophagocytic killing assay (OPKA) was done to evaluate the immune responses against serotypes 19F and 19A. Results: According to the ELISA, all subjects had antibody titers ${\geq}0.35{\mu}g/mL$ for serotypes 19F and 19A in the booster and primary group and 83.0% and 66.7% in the control group, respectively. According to the OPKA, subjects with opsonic activity (${\geq}20$) against serotypes 19F and 19A were 100% and 61.1% of the subjects in the booster group and 66.7% and 19.0% in the primary group, respectively. No subjects in the control group had opsonic antibodies against both serotypes. Conclusion: In conclusion, in children 12-23 months age who were previously vaccinated with PCV7, a cross-reactive immune response is elicited against serotype 19A after a primary series of 3 doses in a small proportion of subjects, and this response is amplified after booster vaccination.

• Pediatric Infection and Vaccine
• /
• 제4권2호
• /
• pp.240-256
• /
• 1997

목 적 : 초등학생의 성별, 연령별, 예방 접종률, 접종 완성률, 접종 시기를 비교하고, 간염 표지자 양성률을 검토하여 경기도 지역에서 과거 15년 동안 영아, 유아 및 초등학생을 대상으로 병의원, 보건소 및 학교 등에서 실시한 B형 간염 예방 접종 실태를 파악하고자 하였다. 방 법 : 1993년에 경기도 지역 초등학교 학생들을 집락 추출(cluster sampling)하여 실시하였다. 학교마다 각 학년별로 한 학급을 선정하여 총 2,072 명을 대상으로 혈청학적 검사와 설문 조사를 실시하였다. 결 과 : 1) 성별 HBsAg 양성률은 남자 3.7%, 여자 2.7%였고, 평균 3.4%였다. 연령별 HBsAg 양성률은 7세 3.5%, 12세 5.2%로 연령이 증가함에 따라 높아지는 경향을 보였다. 2) 어머니들의 B형 간염 출산 전 수검율은 10.2%, 출산 후 수검율은 42.5% 였다. 부모의 학력이 높을수록, 아버지의 직업이 사무직인 경우에 출산 전, 출산 후 수검율이 높았다. 3) 전체 예방 접종률은 82.6%, 접종 완성률은 69.8%, 추가 접종률은 42.8%였다. 연령이 증가함에 따라 예방 접종률, 접종 완성률, 추가 접종률이 모두 감소하였다. 부모의 학력이 높을 수록 예방 접종률, 접종 완성률, 추가 접종률이 증가하였다. 연령이 어릴수록 1 세 미만에 접종한 비율이 증가하였고, 7세 이상에 접종한 비율은 감소하였다. 부모의 학력이 높을수록, 아버지의 직업이 사무직인 경우에 1세 미만에 접종한 비율이 높았다. 4) 예방 접종 시기에 따른 간염 표지자 양성률에서 HBsAg과 Anti-HBc 양성률은 1~6세, 7세 이후, 1 세 미만의 순서로 높았다. 접종회수가 증가함에 따라 Anti-HBs 양성률은 유의하게 증가하였다. 기본 3회 접종 후 5년째 된 군에서 Anti-HBs 양성률은 85.7%, 유효 역가율은 69.6% 로 가장 낮았다. 결 론 : 이상의 결과를 통하여 전체 접종률은 82.6%, 접종 완성률은 69.8% 로 아직 낮은 수준으로 나타났다. 특히 부모의 학력이 낮고 아버지 직업의 사회적 지위가 낮은 계층은 출산 전 출산 후 산모의 HBV 수검율, 자녀의 백신 접종률, 접종 완성률이 모두 낮은 것으로 보아 의료 기관의 접근도가 떨어지고 예방 접종의 중요성에 대한 인식도 낮은 것으로 생각된다. 앞으로 B 형 간염 예방 접종 사업은 지속적인 보건 교육과 함께 이러한 사회적 지위가 낮은 계층 자녀의 접종률을 높이는 특별 관리 대책이 필요하리라 생각된다.

• IMMUNE NETWORK
• /
• 제22권4호
• /
• pp.31.1-31.3
• /
• 2022

• Genomics & Informatics
• /
• 제21권4호
• /
• pp.50.1-50.9
• /
• 2023

Vaccine development is one of the key efforts to control the spread of coronavirus disease 2019 (COVID-19). However, it has become apparent that the immunity acquired through vaccination is not permanent, known as the waning effect. Therefore, monitoring the proportion of the population with immunity is essential to improve the forecasting of future waves of the pandemic. Despite this, the impact of the waning effect on forecasting accuracies has not been extensively studied. We proposed a method for the estimation of the effective immunity (EI) rate which represents the waning effect by integrating the second and booster doses of COVID-19 vaccines. The EI rate, with different periods to the onset of the waning effect, was incorporated into three statistical models and two machine learning models. Stringency Index, omicron variant BA.5 rate (BA.5 rate), booster shot rate (BSR), and the EI rate were used as covariates and the best covariate combination was selected using prediction error. Among the prediction results, Generalized Additive Model showed the best improvement (decreasing 86% test error) with the EI rate. Furthermore, we confirmed that South Korea's decision to recommend booster shots after 90 days is reasonable since the waning effect onsets 90 days after the last dose of vaccine which improves the prediction of confirmed cases and deaths. Substituting BSR with EI rate in statistical models not only results in better predictions but also makes it possible to forecast a potential wave and help the local community react proactively to a rapid increase in confirmed cases.

• Clinical and Experimental Vaccine Research
• /
• 제12권1호
• /
• pp.82-84
• /
• 2023

There were growing reports of herpes zoster reactivation after the coronavirus disease 2019 (COVID-19) vaccination, including a more severe form, herpes zoster ophthalmicus (HZO). A 35-year-old male presented HZO in his left V1 dermatome 10 days after his COVID-19 vaccine booster with Moderna (messenger RNA-1273). He had no history of chronic disease, immunocompromised, autoimmune, malignancy, or long-term immunosuppressive drug use. The rash improved without any further complications after being treated with oral valacyclovir for 7 days. This was a unique case of HZO after the COVID-19 vaccine in a booster setting in healthy younger adults. The association of herpes zoster after a COVID vaccine remained inconclusive and potentially coincidental, especially without the known risk factor. However, we would like to add a report to increase awareness among physicians and the general population, for early recognition and treatment with an antiviral.

• Pediatric Infection and Vaccine
• /
• 제8권2호
• /
• pp.150-159
• /
• 2001

목 적 : 현재 사용하고 있는 마우스 뇌조직 유래 Nakayama주 사백신 접종 방법의 의학적 타당성을 알아보고자 접종 실태와 부작용 발생 양상과 빈도를 조사하고 추가 접종 방법의 타당성을 확인하기 위하여 중화항체 지속률을 조사하였다. 방 법 : 15,487명의 접종아를 대상으로 이상반응 발생 여부를 조사하였고 초등학교 학생 2,277명을 대상으로 건강기록부와 설문지조사를 통하여 접종실태와 이상반응 발생 빈도를 확인하였으며 접종기록이 일치하는 311명의 학생을 대상으로 중화항체 검사를 시행하였다. 검사는 United States Armed Forces Research Institute of Medical Science/Department of Virology, Bangkok(USAMC-AFRIMS)에서 시행되었고 50% 플라크 감소를 기준으로 1 : 10 이상을 양성으로 하였다. 결 과 : 건강기록부에 의한 초등학생 2,277명의 접종률은 47.5%였으나 설문지 조사에서는 접종률이 93.5%로 큰 차이가 있었다. 건강기록부에 나타난 취학 전 접종률은 남자 48.5%, 여자 46.4%로 차이가 없었다. 연령이 증가함에 따라 일본뇌염의 접종 횟수도 증가하는 양상을 보였다. 예방접종 여부가 건강기록부와 설문지 조사 결과가 일치하는 경우는 95년과 96년에 모두 접종 받았다고 응답한 경우만 75.6%로 높았고 그 외에는 일치도가 낮았다. 일본뇌염 예방접종 장소는 학교가 60.1%로 가장 많았고 그 외 보건소가 25.1%, 병 의원 14.1% 순이었다. 1995년 5~6월 사이 서울 소재 보건소에서 15,487명을 대상으로 일본뇌염 사백신을 접종한 후 0.13%에서 이상반응이 발생하여 의료 기관을 방문하였으며 이 중 57%는 고열 때문이었고 1례에서 접종 후 3분만에 실신 발작이 있었다. 전체 접종자의 0.02%에서 심한 두드러기 반응으로 의료기관을 방문하였으며 0.03%에서 두통 및 구토 등으로 의료 기관을 다시 찾았다. 1996년 봄에 초등학생을 대상으로 시행한 이상반응 설문지 조사에 의하면 주사 부위 발적이 17.4%, 주사 부위 동통이 14.8%, 발열 4.3%였고 그 외에 두통, 구토, 반점 등이 관찰되었다. 초등학생 311명 중 일본뇌염 접종력 조사에서 마지막 접종 후 6개월이 경과한 경우(1군)가 155명, 접종 후 18개월이 경과한 경우(2군) 104명, 30개월이 경과한 경우(3군)이 45명, 42개월이 경과한 경우(4군)가 7명이었다. 이들의 항체 양성률은 1군이 98.1%(152/155), 2군이 99.0%(103/104), 3군이 95.6%(43/45), 4군이 71.4%(5/7)로 양성률에 있어서 각 군간의 차이는 없는 것으로 나타났다. 결 론 : 현재 격년으로 시행하고있는 일본뇌염 사백신 추가 접종은 시기를 늘려 시행하여도 항체 지속률을 유지할 수 있을 것으로 추정된다.